Arcus Biosciences (RCUS) Total Non-Current Liabilities (2017 - 2025)
Historic Total Non-Current Liabilities for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $386.0 million.
- Arcus Biosciences' Total Non-Current Liabilities fell 3555.93% to $386.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $386.0 million, marking a year-over-year decrease of 3555.93%. This contributed to the annual value of $508.0 million for FY2024, which is 346.23% up from last year.
- According to the latest figures from Q3 2025, Arcus Biosciences' Total Non-Current Liabilities is $386.0 million, which was down 3555.93% from $367.0 million recorded in Q2 2025.
- Arcus Biosciences' 5-year Total Non-Current Liabilities high stood at $733.0 million for Q1 2022, and its period low was $260.1 million during Q1 2021.
- Its 5-year average for Total Non-Current Liabilities is $490.7 million, with a median of $503.0 million in 2022.
- Per our database at Business Quant, Arcus Biosciences' Total Non-Current Liabilities surged by 64608.5% in 2021 and then plummeted by 3555.93% in 2025.
- Arcus Biosciences' Total Non-Current Liabilities (Quarter) stood at $628.4 million in 2021, then fell by 19.96% to $503.0 million in 2022, then decreased by 2.39% to $491.0 million in 2023, then grew by 3.46% to $508.0 million in 2024, then fell by 24.02% to $386.0 million in 2025.
- Its Total Non-Current Liabilities was $386.0 million in Q3 2025, compared to $367.0 million in Q2 2025 and $459.0 million in Q1 2025.